Key Performance Indicators 2011
Unitaid strategy 2010-2012
Key Performance Indicators 2010
Unitaid audited financial report for period 2008-2009
Key Performance Indicators 2009
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Equitable access to therapeutics for pandemic preparedness and response
Overview of mpox antivirals and diagnostics landscape
Next generation pulse oximeters technology and market landscape
Malaria diagnostics market and technology landscape
Landscape of innovative tools and delivery strategies for eliminating vertical transmission of HIV, syphilis, hepatitis B, and chagas in endemic areas
Multipurpose prevention technologies: Technology landscape and potential for low- and middle-income countries
Screening and treatment for Chagas disease – technology and market landscape
Biomarkers for acute febrile illness at the point-of-care in low-resource settings. Technical working session. Meeting pre-reads
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Landscape for HIV rapid diagnostic tests for HIV self-testing – 1st edition – Dec 2015
Strategic narrative: Hepatitis C in the context of co-infection with HIV
Hepatitis C medicines technology and market landscape – update
Tuberculosis diagnostics technology and market landscape – 4th edition
Tuberculosis diagnostics market in select high-burden countries current market and future opportunities for novel diagnostics
HIV/AIDS diagnostics technology landscape – 5th edition
Key Performance Indicators 2015
Patent landscape: velpatasvir
